FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4322505893> ?p ?o ?g. }

• W4322505893 endingPage "197" @default.
• W4322505893 startingPage "191" @default.
• W4322505893 abstract "To evaluate the safety and efficacy of second-line metronomic oral vinorelbine-atezolizumab combination for stage IV non-small-cell lung cancer.This was a multicenter, open-label, single-arm Phase II study performed in patients with advanced NSCLC without activating EGFR mutation or ALK rearrangement who progressed after first-line platinum-doublet chemotherapy. Combination treatment was atezolizumab (1200 mg IV day 1, every 3 weeks) and oral vinorelbine (40 mg, 3 times by week). The primary outcome was progression-free survival (PFS) during the 4-month follow-up from the first dose of treatment. Statistical analysis was based on the exact single-stage Phase II design defined by A'Hern. Based on literature data, the Phase III trial threshold was set at 36 successes in 71 patients.71 patients were analyzed (median age, 64 years; male, 66.2%; ex-smokers/active smokers, 85.9%; ECOG performance status 0-1, 90.2%; non-squamous NSCLC, 83.1%; PD-L1 ≥ 50%, 4.4%). After a median follow-up of 8.1 months from treatment initiation, 4-month PFS rate was 32% (95% CI, 22-44), i.e. 23 successes out 71 patients. OS rate was 73.2% at 4 months and 24.3% at 24 months. Median PFS and OS were 2.2 (95% CI, 1.5-3.0) months and 7.9 (95% CI, 4.8-11.4) months, respectively. Overall response rate and disease control rate at 4 months were 11% (95% CI, 5-21) and 32% (95% CI, 22-44), respectively. No safety signal was evidenced.Metronomic oral vinorelbine-atezolizumab in the second-line setting did not achieve the predefined PFS threshold. No new safety signal was reported for vinorelbine-atezolizumab combination." @default.
• W4322505893 created "2023-02-28" @default.
• W4322505893 creator A5015766588 @default.
• W4322505893 creator A5016370905 @default.
• W4322505893 creator A5032332349 @default.
• W4322505893 creator A5033220886 @default.
• W4322505893 creator A5035722823 @default.
• W4322505893 creator A5039128537 @default.
• W4322505893 creator A5041702683 @default.
• W4322505893 creator A5044886899 @default.
• W4322505893 creator A5047402540 @default.
• W4322505893 creator A5064696120 @default.
• W4322505893 creator A5070368240 @default.
• W4322505893 creator A5071449669 @default.
• W4322505893 creator A5072758102 @default.
• W4322505893 creator A5082965263 @default.
• W4322505893 creator A5091671421 @default.
• W4322505893 date "2023-04-01" @default.
• W4322505893 modified "2023-10-05" @default.
• W4322505893 title "Safety and efficacy of second-line metronomic oral vinorelbine-atezolizumab combination in stage IV non-small-cell lung cancer: An open-label phase II trial (VinMetAtezo)" @default.
• W4322505893 cites W1972146805 @default.
• W4322505893 cites W2120113475 @default.
• W4322505893 cites W2139240866 @default.
• W4322505893 cites W2160298546 @default.
• W4322505893 cites W2210453860 @default.
• W4322505893 cites W2293531514 @default.
• W4322505893 cites W2502096301 @default.
• W4322505893 cites W2567564314 @default.
• W4322505893 cites W2574335147 @default.
• W4322505893 cites W2599559355 @default.
• W4322505893 cites W2755002661 @default.
• W4322505893 cites W2784371446 @default.
• W4322505893 cites W2905538776 @default.
• W4322505893 cites W2969575102 @default.
• W4322505893 cites W2970707725 @default.
• W4322505893 cites W2997852046 @default.
• W4322505893 cites W3090664821 @default.
• W4322505893 cites W3092262112 @default.
• W4322505893 cites W3131267412 @default.
• W4322505893 cites W3138581479 @default.
• W4322505893 cites W3155595713 @default.
• W4322505893 cites W3170017808 @default.
• W4322505893 cites W3170951565 @default.
• W4322505893 cites W4210992155 @default.
• W4322505893 cites W4220783622 @default.
• W4322505893 cites W4292661228 @default.
• W4322505893 doi "https://doi.org/10.1016/j.lungcan.2023.02.020" @default.
• W4322505893 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36868180" @default.
• W4322505893 hasPublicationYear "2023" @default.
• W4322505893 type Work @default.
• W4322505893 citedByCount "2" @default.
• W4322505893 countsByYear W43225058932023 @default.
• W4322505893 crossrefType "journal-article" @default.
• W4322505893 hasAuthorship W4322505893A5015766588 @default.
• W4322505893 hasAuthorship W4322505893A5016370905 @default.
• W4322505893 hasAuthorship W4322505893A5032332349 @default.
• W4322505893 hasAuthorship W4322505893A5033220886 @default.
• W4322505893 hasAuthorship W4322505893A5035722823 @default.
• W4322505893 hasAuthorship W4322505893A5039128537 @default.
• W4322505893 hasAuthorship W4322505893A5041702683 @default.
• W4322505893 hasAuthorship W4322505893A5044886899 @default.
• W4322505893 hasAuthorship W4322505893A5047402540 @default.
• W4322505893 hasAuthorship W4322505893A5064696120 @default.
• W4322505893 hasAuthorship W4322505893A5070368240 @default.
• W4322505893 hasAuthorship W4322505893A5071449669 @default.
• W4322505893 hasAuthorship W4322505893A5072758102 @default.
• W4322505893 hasAuthorship W4322505893A5082965263 @default.
• W4322505893 hasAuthorship W4322505893A5091671421 @default.
• W4322505893 hasConcept C121608353 @default.
• W4322505893 hasConcept C126322002 @default.
• W4322505893 hasConcept C141071460 @default.
• W4322505893 hasConcept C143998085 @default.
• W4322505893 hasConcept C2775949291 @default.
• W4322505893 hasConcept C2776256026 @default.
• W4322505893 hasConcept C2776694085 @default.
• W4322505893 hasConcept C2777701055 @default.
• W4322505893 hasConcept C2778239845 @default.
• W4322505893 hasConcept C2780030458 @default.
• W4322505893 hasConcept C2780350996 @default.
• W4322505893 hasConcept C31760486 @default.
• W4322505893 hasConcept C71924100 @default.
• W4322505893 hasConcept C90924648 @default.
• W4322505893 hasConceptScore W4322505893C121608353 @default.
• W4322505893 hasConceptScore W4322505893C126322002 @default.
• W4322505893 hasConceptScore W4322505893C141071460 @default.
• W4322505893 hasConceptScore W4322505893C143998085 @default.
• W4322505893 hasConceptScore W4322505893C2775949291 @default.
• W4322505893 hasConceptScore W4322505893C2776256026 @default.
• W4322505893 hasConceptScore W4322505893C2776694085 @default.
• W4322505893 hasConceptScore W4322505893C2777701055 @default.
• W4322505893 hasConceptScore W4322505893C2778239845 @default.
• W4322505893 hasConceptScore W4322505893C2780030458 @default.
• W4322505893 hasConceptScore W4322505893C2780350996 @default.
• W4322505893 hasConceptScore W4322505893C31760486 @default.
• W4322505893 hasConceptScore W4322505893C71924100 @default.
• W4322505893 hasConceptScore W4322505893C90924648 @default.
• W4322505893 hasFunder F4320307779 @default.
• W4322505893 hasFunder F4320334242 @default.

• next